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Highlights 
 
 Intranasal self-administration of fentanyl was associated with few maternal side effects. 
 A trend for increased adverse events and neonatal respiratory support occurred with higher doses. 






PATIENT-CONTROLLED INTRANASAL FENTANYL ANALGESIA: A PILOT STUDY TO 2 
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Short Title 5 
Patient-controlled intranasal fentanyl analgesia for childbirth 6 
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ABSTRACT (n= 250) 28 
Background: 29 
Intranasal administration of fentanyl is a non-invasive method of analgesic delivery which has been 30 
shown to be effective for relieving pain. This pilot study aimed to assess the practicality and 31 
tolerability of patient-controlled intranasal fentanyl for relieving pain during childbirth. 32 
Methods: 33 
This prospective, non-randomised, clinical trial recruited women with a singleton pregnancy during 34 
November 2009 to October 2011. Exclusion criteria included respiratory disease, gestation <37 weeks 35 
and pregnancy complication. The device administered 54 mcg of fentanyl per spray, incorporating a 36 
3-minute lock-out. Data included demographics, dose, additional analgesia, adverse events, pain relief 37 
and delivery outcomes. Follow-up data was obtained within 48 hours regarding tolerability of the 38 
device. Data is presented as descriptive statistics. 39 
Results: 40 
The final sample included 32 women: mean age 28.7 years and gestation 39.8 weeks. Average 41 
fentanyl dose was 733.9 mcg and duration of use was 3.5 hours. Most women (78.2%) reported 42 
„satisfactory‟ to „excellent‟ pain relief using the nasal device. Four neonates (12.5%) required bag-43 
mask ventilation at birth: three had adequate respirations within 5 minutes and 1 required short-term 44 
observation in special-care-nursery. For all items, there was a trend towards an adverse outcome, 45 
including neonatal respiratory support, as the dose increased. On follow-up, 84.4% reported they 46 
would use intranasal fentanyl for their next childbirth experience. 47 
Conclusions: 48 
Patient-controlled intranasal fentanyl provides an acceptable level of analgesia during childbirth, 49 
however, may increase the risk of respiratory depression for neonates. Future, randomised studies 50 
might evaluate the safety and efficacy of patient-controlled intranasal fentanyl compared with existing 51 
analgesia options. 52 
Key-words: analgesia, childbirth, fentanyl, intranasal, obstetric, patient-controlled. 53 




Birthing may be the most severe pain experience for most women. In Australia, various methods of 56 
analgesia are available to birthing women, including pharmacological (systemic and epidural 57 
analgesic)
1-3
 and non-pharmacologic techniques (e.g. continuous birthing support, aromatherapy, 58 





Systemic birthing analgesia includes inhaled nitrous oxide and systemic opioids. In Australia, 62 
pethidine has been the traditional opioid of choice.
5
 Opioid administration is associated with maternal 63 
side effects including nausea and vomiting, respiratory depression, and delayed gastric emptying. All 64 
opioids cross the placenta, and can result in neonatal side effects including respiratory depression, 65 




Doubt has been cast on the suitability of opioid analgesia for birthing pain because of the high 68 
incidence of maternal and neonatal adverse effects and inadequate analgesia it provides.
2
 In addition, 69 
there are considerable doubts about the effectiveness of pethidine including the slow onset of action.
7
 70 
A recent Cochrane review identified a lack of research regarding the efficacy of opioid analgesia, 71 
which opioid is most effective, and strategies to minimize adverse side effects.
8
 At best, they found 72 
moderate maternal satisfaction with opioid analgesia. 73 
 74 
Currently the options for effective labour analgesia are limited. Prolonged and unrelieved pain may 75 
cause patient dissatisfaction and is associated with postpartum depression and posttraumatic stress 76 
disorder.
9,10
 The „gold standard‟ for birthing analgesia is epidural analgesia, which provides superior 77 
analgesia without maternal sedation.
2
 However, many women choose not to have an epidural and 78 
some women are unable to have an epidural due to co-existing contra-indications (e.g. coagulopathy, 79 
spinal pathology), fear of needles, and absence of skilled staff (e.g., an anaesthetist to insert the 80 
catheter or midwifery staff trained in the management of epidurals, etc). Epidural analgesia is 81 
associated with an increased risk of instrumental vaginal delivery, prolongation of second stage and 82 
increased oxytocin requirement.
11
 Leeman et al.
12
 questioned if the high use of epidural analgesia is 83 
really the true preference among women in the United States or if it is chosen because there is a lack 84 
of acceptable options. They recommended further research investigating women‟s preferences 85 
regarding analgesia during childbirth. 86 
 87 
Fentanyl is a synthetic opioid analgesic and may be administered via several routes, most commonly 88 
via epidural injection or intravenously (IV), both of which are invasive. After neuraxial block, women 89 
may be restricted to bed and have limited mobility for a significant period of time which may impact 90 
negatively on maternal satisfaction and delivery. 91 
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Drugs, including fentanyl, may cross the placenta to the fetus. However, serum fentanyl levels in the 92 
fetus have been found to be significantly lower than maternal serum levels. Furthermore, respiratory 93 
depression has been found to be rare in babies born to mothers receiving fentanyl either parenterally 94 




Maternal satisfaction during birthing has been widely studied. Behaviours that encourage involvement 97 
and participation in decision-making during birthing promote feelings of control, coping and feeling 98 
supported, facilitating a woman‟s assessment of their birth experience as positive.
16
 Patient-controlled 99 
epidural analgesia has been associated with improved maternal satisfaction and lower volume of local 100 




Intranasal fentanyl has been proposed as an alternative, fast-acting and non-invasive method of 103 





, post operative pain
24-26
, and breakthrough cancer pain.
27
 Fentanyl 105 
administration via intranasal patient controlled analgesia (PCA) has been found to be as effective as 106 
IV PCA for post operative analgesia.
26, 28
 To our knowledge, self-administered intranasal fentanyl has 107 
not been used in the obstetric setting. 108 
 109 
The administration of patient-controlled intranasal fentanyl (PCINF) may positively affect the birthing 110 
experience by virtue of being less invasive and portable, having a short duration of action and 111 
effectively relieving childbirth pain. This pilot study aimed to assess the practicality and tolerability of 112 




This was a prospective, non-randomised, open clinical study registered with the Australian and New 117 
Zealand Clinical Trials Registry. Ethics approval was obtained from the Melbourne Health Human 118 
Research Ethics Committee. Informed and written consent was obtained from all participants in the 119 
ante-natal period. 120 
Recruitment 121 
Women were recruited from one hospital site during November 2009 to October 2011. With over 122 
3500 deliveries per year, it was at the time of the study the third largest obstetric facility in the major 123 
metropolitan area. Women who presented to this facility for antenatal care and who fulfilled the study 124 





To be eligible, women had to be at least 18 years of age and 37 weeks gestation at the time of 128 
presentation and in labour. In addition, they needed to be able to self-administer PCINF and speak and 129 
read English. Exclusion criteria included: 1) presence of pregnancy–related medical condition (e.g. 130 
pregnancy induced hypertension, pre-eclampsia, gestational diabetes); 2) abnormal fetal lie (e.g. 131 
breech); 3) placental abnormalities detected during ante-natal assessment; 4) non-singleton 132 
pregnancy; 5) allergy to opioids; 6) asthma; 7) myasthenia gravis; 8) opioid tolerance (e.g. regular use 133 
of methadone, buprenorphine, heroin, morphine, oxycodone) and 9) chronic nasal problems (e.g. hay-134 
fever, sinusitis). Eligibility criteria were re-assessed by the treating midwife. Women who had 135 
previously consented to participate, but when they presented in labour had an exclusion criteria (for 136 
example; pre-eclampsia or breech presentation, etc), were no longer eligible. 137 
 138 
Intervention 139 
Women fulfilling all study criteria were able to request a PCINF device for pain relief after presenting 140 
to the delivery suite in labour. The devices were prepared in advance and available for all women at 141 
hospital presentation. Women were informed that they had no obligation to use the PCINF device and 142 
that it was available as an analgesic option if, and when, they requested it. 143 
 144 
Fentanyl (300mcg per mL), manufactured and supplied by Orion Laboratories (Western Australia, 145 
Australia), was used to fill the Go Medical nasal pump device, purchased from Admedus, Australia 146 
(Figure 1). The single use PCINF devices, as prepared for this study, contained 450mcg of Fentanyl 147 
(1.5ml) in total, delivered 54mcg (0.18mL) per atomised spray thus enabling eight atomised sprays 148 
per device. Following demand activation, the device flow control tubing is re-loaded over 3 minutes. 149 
During this refill interval, a partial pro-rata dose can be delivered by pump activation, thus limiting 150 
the frequency of full dose administration. At the time of the study, St John Ambulance guidelines 151 
(Western Australia) recommended a loading dose of 180mcg, followed by 56mcg boluses at 5-152 
minutely intervals. (Informal evidence, 2010) We proposed 54mcg at 3-minute intervals with no 153 
loading dose, in lieu of severity of pain and requirement for more frequent doses, in comparison to 154 
patients receiving care in an ambulance for a short period of time. 155 
 156 
Several safety precautions were exercised including frequent vital sign assessment, restricted volume 157 
in a single device and a limit of four devices per participant. To monitor for opioid-induced 158 
ventilatory impairment (OIVI), participants were monitored continuously by their allocated midwife 159 
for sedation, respiratory rate, heart rate, blood pressure, pulse oximetry and fetal heart rate. OIVI, 160 
assessed by respiratory rate and sedation score, was determined between contractions. Sedation score 161 
was assessed according to standard hospital assessment procedures and the following criteria: “Alert”, 162 
“Mild” (sometimes drowsy, easily roused, stays awake once woken), “Moderate” (often drowsy, 163 
easily roused, unable to stay awake once woken), “Severe” (Often drowsy, difficult to rouse or a 164 
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respiratory rate <10), or “Asleep” (stirs to touch). Use of the PCINF device was discontinued for any 165 
woman who experienced moderate or severe sedation, along with increased frequency of observations 166 
and oxygen administration. 167 
 168 
Due to pain severity
5
, we estimated that women in this study would require higher doses of fentanyl 169 
than may have been used to manage other types of pain. After completing one device a woman was 170 
provided with a further PCINF device provided she did not show significant adverse effects including 171 
opioid-induced ventilatory impairment (moderate or severe sedation and/or respiratory rate < 10/min), 172 
systolic blood pressure < 90mmHg, heart rate < 50 beats per minute, nausea and/or vomiting not 173 
relieved by anti-emetic or abnormal fetal heart rate or variability. Initially, a limit of four PCINF 174 
devices was set (maximum possible fentanyl dose of 1800mcg). This maximum allowable dose was 175 
revised down to 1350mcg following the observation that three women experienced a moderate level 176 
of sedation at the higher dose. Standard practice in the birthing unit in which this study was conducted 177 
was that Pethidine is given relatively early in labour, and then avoided as labour progresses, so as to 178 
reduce the risk of neonatal opioid side effects. Midwives carefully assess women's progress in labour 179 
and the appropriateness of administering opioid analgesia. When women are judged to be in 180 
transition, opioid analgesia is usually withheld. In keeping with standard practice, PCINF 181 
administration was suspended during second stage of labour. 182 
 183 
The woman and her support person(s) were educated about use of the PCINF device, including 184 
instructions not to share the device and its‟ contents with another person. The PCINF was carried by 185 
the participant in a pouch supported by a lanyard fastened around their neck for easy access during 186 
mobilisation. Women were advised that the device would not totally alleviate their pain and that they 187 
should discontinue self-administration if they felt excessively drowsy or light-headed. In addition, 188 
vital signs were measured at 30-minute intervals to detect hypotension. 189 
 190 
Trial participation did not preclude women from requesting and receiving other modes of pain relief 191 
including intramuscular pethidine, nitrous oxide and epidural analgesia. However, PCINF was 192 
discontinued before alternative opioid analgesia or epidural analgesia was administered. Women were 193 
able to co-administer nitrous oxide and PCINF. 194 
 195 
Data Collection 196 
An explicit data form was used by midwives during PCINF use to record information related to the 197 
study. Data were collected by midwives and included: demographic data (age, ethnicity, primary 198 
language spoken), pregnancy-related information (birthing support, induced or natural labour, parity, 199 
gestation) and routine observations. Throughout use of the PCINF device routine observations were 200 
recorded at 30-minutely intervals including vital signs (heart rate; blood pressure; oxygen saturation; 201 
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respiratory rate), sedation score, fetal heart rate and any adverse effects. The number of PCINF 202 
devices used, additional analgesia administered, difficulties with use of the device and mode of 203 
delivery were documented. After delivery, neonatal outcomes including Apgar score at birth and at 5-204 
minutes, and the requirement for respiratory support or naloxone were also recorded. 205 
 206 
The primary outcome measure was pain relief using a subjective measure. Pain relief was measured 207 
between contractions at 30-minute intervals using a 5 point Likert-type scale (a lot, moderately, a little 208 
bit, not at all, not sure). These descriptions for pain relief were used in this study to simplify 209 
explanations of the pain scale to women during labour. Within 24 to 48 hours of delivery, women 210 
were interviewed in hospital or by telephone to obtain the following data: adverse effects; ease of use; 211 
and intention to use PCINF for future births. Women were also asked whether they would use PCINF 212 
in future birthing episodes. 213 
 214 
Data analysis 215 
IBM SPSS for Statistics
29
 was used for data storage and analysis. Mean and range are presented for 216 
continuous data which was normally distributed and proportions for categorical data. This was a pilot 217 
study designed to test the practicality and tolerability of PCINF for women during childbirth; 218 
therefore no sample size estimation was calculated prior to conduct of the study, nor were differences 219 
compared by univariate analysis. 220 
 221 
RESULTS 222 
Seventy-nine women were recruited to participate in the study in the antenatal period. However, 44 223 
women did not use the PCINF device for reasons including analgesia not required, elective caesarean 224 
section, or alternative analgesia use. In addition, three further women were excluded from 225 
participation for reasons including emergency caesarean, presentation in second stage and faulty 226 
device. In regards to the faulty device, contents of the vial were not expelled after depression of the 227 
vial. The woman declined to accept a new device and opted for alternative analgesia.  228 
 229 
The final sample included 32 women with a mean age of 28.7 years and gestation of 40 weeks. 230 
Fentanyl use, demographics and birthing characteristics are shown in Table 1. The average fentanyl 231 
dose was 733.9 mcg and duration of use was 3.5 hours. Nineteen (59.4%) used nitrous oxide in 232 
addition to PCINF. Nine women (28.1%) discontinued PCINF use when they requested alternative 233 
analgesia (pethidine (2, 6.3%) and epidural (7, 21.9%).  234 
 235 
Maternal and neonatal outcomes are provided in Table 2. Pain relief was achieved, as an average for 236 
duration of PCINF use, in the following proportions: “A lot” (26.2%), “Moderately” (21.6%), “Little 237 
Bit” (27.9%), “Not at all” (18.7%) and “Not Sure” (2.1%). On follow-up, 27 women (84.4%) reported 238 
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they would ask for PCINF device for future birthing experiences. When asked about the overall 239 
impact on pain relief during birthing, the majority of participants (78.2%) found PCINF to be at least 240 
satisfactory for relieving pain (excellent: 34.4%, good: 21.9%, satisfactory: 21.9%). Twenty-eight 241 
women (87.5%) found the device easy to use. 242 
 243 
Three women (9.4%) were moderately sedated after using PCINF, resulting in discontinuation of 244 
PCINF treatment. For two of these women, the neonate had a low Apgar score at birth (3 and 4) but 245 
achieved an adequate score within 5 minutes after birth (8 and 9). Thirteen (40.6%) women 246 
experienced adverse effects, including nausea (31.3%), vomiting (31.3%), headache (3.1%) and nasal 247 
irritation (12.5%). 248 
 249 
The majority of infants had an Apgar score of at least 7 at birth (84.4%) and at 5 minutes (93.7%). 250 
Ten neonates (31.3%) required some form of respiratory support at birth. Additional detail regarding 251 
these neonates is provided in Table 3. Positive pressure ventilation (Neo-Puff) was administered to 252 
four neonates with Apgar scores of 1, 3, 4 & 7 at birth. These scores improved within 5 minutes (6, 9, 253 
8 & 9; respectively). One neonate with concurrent heart murmur and congenital ear problems was 254 
transferred to special care nursery for ongoing assessment. Continuous positive airway pressure 255 
(CPAP) using air was administered to six neonates, who all recovered without requirement for 256 
naloxone. Without diminishing the fact that approximately a third of neonates (n=10) in this study 257 
experienced an adverse outcome, eight (Table 3) had a co-existing factor which might have 258 
contributed to their adverse condition. In the neonates who required respiratory support at birth, the 259 
following factors were co-existent: cardiotocography (CTG), deceleration (n=2), meconium staining 260 
(n=2), cephalo-pelvic disproportion (CPD) (n=2), cord around neck (n=1) and shoulder dystocia 261 
(n=1). 262 
 263 
Adverse outcomes including low Apgar scores (<7) at birth, requirement for neonate respiratory 264 
support (CPAP or NeoPuff), and moderate maternal sedation in relation to cumulative fentanyl dose, 265 
are presented in Table 4. For all outcomes, there was a trend towards an adverse outcome as the dose 266 
increased.  267 
 268 
DISCUSSION 269 
To our knowledge, this is the first study to assess PCINF use during birthing. This pilot study found 270 
that PCINF using a 3-minute lock-out device provided a high level of satisfaction for women during 271 
childbirth. The majority of participants (84.4%) expressed a willingness to use PCINF in future 272 
birthing experiences. One of the distinct advantages of PCINF lies with its‟ application as a self-273 
administered analgesic. McCrea and Wright
30 
found that feelings of personal control positively 274 
influence women's satisfaction with pain relief during birthing. A study by Fenwick et al.
31
 confirmed 275 
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that women prefer to be involved and to participate in decision making during their birthing 276 
experience. So it may be that the main advantage of PCINF lies with its‟ application as a self-277 
administered analgesic, facilitating a sense of self-efficacy. This would require further investigation. 278 
 279 
While the device was acceptable to most of the participants, it is interesting that approximately half of 280 
them rated it as providing little to no relief of pain when evaluated between contractions. A recent 281 
Cochrane review
32
 found that there is insufficient evidence regarding the effectiveness of parenteral 282 
opioids, and high quality trials are needed. Pharmacologic options for women in Australia are limited 283 
to inhaled nitrous oxide , intramuscular opioid, IV PCA opioid and epidural analgesia. Nitrous oxide 284 
inhalation provides minimal pain relief.
2
 Intramuscular injections are painful and opioids may be 285 
associated with unpleasant side effects for both mother and baby including nausea, vomiting, sedation 286 
and respiratory depression.
2
 Fleet et al
33
 have recently reported that intranasal fentanyl was associated 287 
with less sedation scores, anti-emetic use, and epidural use, and higher requirement for nursery 288 
admission for neonates, compared with women receiving pethidine during labour. In that study, 289 
intranasal fentanyl was also associated with greater satisfaction. Epidural infusion may be difficult or 290 
contra-indicated, may restrict the woman to bed rest or delay birthing.
2 It is possible that the PCINF 291 
device does not offer further benefit when compared with IV PCA fentanyl, aside from not requiring a 292 
cannula and the related risk of infection. Pharmacokinetic studies comparing intranasal and IV 293 
administration have shown that onset and duration of analgesia are similar
34-35
. Some of the benefits 294 
of IV PCA over a nasal device include better titratability of administered dose and total hourly 295 
dosage. The portability and accessibility of a nasal spray however makes this mode of delivery more 296 
accessible to women in remote areas. One PCINF device costs approximately $47 Australian dollars, 297 
which makes this an affordable analgesic option. Future studies may compare these two modes of 298 
administration. 299 
 300 
A high rate of nausea and vomiting was found in this current study (nausea, 31.3%, vomiting, 28.1%). 301 
More than half (59.4%) of the women used nitrous oxide inhalation which may also be associated 302 
with these side effects and contributed to analgesia also. In an informal audit, Sinha et al.
3
 found that 303 
50% of women in birthing felt nauseated or vomited. Hence, it is unclear if side effects experienced 304 
were in response to fentanyl alone, nitrous oxide alone or both, or was a normal physiological 305 
response to the visceral pain of birthing. It is likely to be multifactorial. 306 
 307 
In this study, ten babies (31.3%) required respiratory support after birth. In response, the study 308 
protocol was amended to a limit of 1350mcg for the duration of 1
st
 stage, cessation of PCINF use in 309 
2
nd
 stage, and discontinuation if the woman had moderate or severe sedation, or had a respiratory rate 310 
less than ten. No neonate received naloxone throughout the study period & none required Neopuff 311 
support after the protocol amendment. There was a suggestion that higher doses of fentanyl were 312 
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associated with an increased requirement for neonatal respiratory support and maternal sedation. 313 
Statistical testing of this trend was not performed due to low numbers. Whilst most newborns are 314 
vigorous at birth, the Australian Resuscitation Council reports approximately 10% will require some 315 
breathing assistance at birth
36
. Halpern et al.
37
 found that 52% of neonates required active 316 
resuscitation and 17% required naloxone treatment after IV Fentanyl PCA. This would suggest that 317 
PCINF is not inferior to IV PCA Fentanyl. For neonates who required respiratory support at birth, 8 318 
(80%) had confounding variables which may also have contributed to the requirement for 319 
resuscitation e.g., meconium staining, CPD, cord around neck or dystocia.  320 
 321 
Our study found that women in childbirth used higher doses of Fentanyl (mean: 733.9mcg) when 322 
compared with the pre-hospital (mean dose: 362mcg) setting.
38 
In a small study evaluating the use of 323 
patient controlled intranasal fentanyl over 8 hours post caesarean, the maximum dose administered 324 
was 319.5 mcg.
39
 Reasons for the higher dose used in our study may be the prolonged duration of 325 
PCINF use (duration of use: mean 3.5 hours, range 1 to 14 hours) and known severity of intra-partum 326 
pain. Higher doses have been reported in studies investigating IV Fentanyl PCA
33, 40 
The findings of 327 
this study may also have been affected by the fact that over one-third of participants had labour 328 
augmented with oxytocin, which may have had a significant impact on pain scores and satisfaction 329 
with the device. Larger, randomised studies should be able to control for confounding factors such as 330 
concomitant analgesia use (e.g., nitrous oxide) and other treatment (e.g., oxytocin). 331 
 332 
LIMITATIONS 333 
A moderate proportion of women who consented to participate in the ante-natal period, did not use the 334 
PCINF device during childbirth, possibly because they changed their mind about participating in the 335 
study or because they did not require analgesia during childbirth. Extensive exclusion criteria limited 336 
enrolment to mainly healthy women. Difficulties in recruiting participants during the antenatal period 337 
has been reported previously.
41
 A follow study could investigate women‟s opinions about the use of 338 
PCINF during birthing. In addition, this was a small pilot study involving 32 women over a 2-year 339 
period, and over half (59.4%) of the women used nitrous oxide inhalation which confounds the data. 340 
 341 
Conclusion 342 
Intranasal self administration of fentanyl in birthing was acceptable to the majority of participants 343 
with few significant maternal side effects, most of which are known to be associated with systemic 344 
opioid analgesics as a class. However, there was a trend for increased adverse events and requirement 345 
for neonatal respiratory support with higher doses.  346 
 347 
There are limited pharmacologic choices for women during childbirth. Self-administered nasal 348 
fentanyl does not compel a woman to bed rest, and may provide a degree of autonomy during the 349 
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birthing experience. A large, randomised study comparing PCINF with other analgesic preparations 350 
(e.g. opioid injection, inhaled nitrous oxide) is required to more fully explore the efficacy and safety 351 
of PCINF. 352 
  353 
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1. PCINF: Patient controlled intranasal fentanyl, 2. LUCS: Lower uterine segment caesarean 396 
  397 
Characteristics   
 Mean Range 
Age (years) 28.7 18 to 39 
Gestation (weeks) 39.8 39 to 41 
  21 65.6% 
  3 9.4% 
  2 6.3% 
  2 6.3% 
  4 12.6% 
  Mean Range 
Average Fentanyl dose (mcg) 733.9 90 to 1800 
Duration of PCINF
1
 use (hours) 3.5  1 to 14 










2 to 26 
0.3 to 3.5 
 No: % 
Previous births 28 89.9% 
Country of birth Australia/New Zealand 21 65.6% 
 Asia 3 9.4% 
 India 2 6.3% 
 Europe 2 6.3% 
 Other 4 12.6% 
Augmentation Nil 16 50.0% 
Prostaglandin 5 15.6% 
Rupture of membranes 1 3.1% 
Oxytocin  12 37.5% 
Nitrous Oxide 19 59.4% 
Mode of Delivery 
 













Table 2 Ante-natal and post-natal outcomes during patient controlled intranasal fentanyl use 398 






















0 to 100 
0 to 100 
0 to 100 
0 to 33.3 

















































Reason for withdrawal 
 
 
















Neonatal Outcomes  No: % 
Apgar Scores at 1-minute 
 
1 to 3 
4 to 6 







Apgar Scores at 5-minutes 
 
1 to 3 
4 to 6 









 10 31.3%  
 Mean Range 
Time to established respirations (minutes) 1.6  1 to 8 
1. PCINF: patient-controlled intranasal fentanyl; 2. LUSC: Lower uterine segment caesarean section; 3. CPAP: Continuous Positive 399 
Airways Pressure  400 
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Birth weight Delivery 
Birthing or Neonate 









Neo-Puff 1 6 1350 7 7.8 30 4740g Instrum
1
 Deceleration, Shoulder 
dystocia 
Neo-Puff 3 9 150 1 9.8 20 3430g NVD
2
 Deceleration, Precipitate 
delivery 
Neo-Puff 4 8 1690 7 8.5 17 3720g Instrum Deceleration, Heart 
murmur, Ear canal 
malformation 





 3 8 900 4 9.0 16 3820g Normal Nil 
CPAP 7 9 1350 7 21.0 NA 3610g LUSC CPD
4
, Deceleration 
CPAP 7 9 660 4 14.0 195 3780g Instrum Deceleration, Meconium 
CPAP 8 9 900 3 20.0 189 4710g LUSC CPD, Meconium 
CPAP 8 8 600 3 7.0 36 3650g NVD Nil 
CPAP 9 6 750 2 2.0 40 3950g NVD Shoulder dystocia, Cord 
around neck 










Duration of use  
range in hours 
Apgar<7  




(n (%)  
Maternal moderate sedation  
n ( %) 
≤ 450 13 (40.6%) 1 - 4  1 (7.7%) 3 (23.1%) 0 
451 to ≤900 11 (34.4%) 2 - 5  3 (27.3%) 4 (36.4%) 1 (9.1%) 
901 to ≤1350 4 (12.5%) 6 - 7  1 (25.0%) 2 (50.0%) 0 
1351 to 1800 2 (6.3%) 7 and 8 1 (50.0%) 1 (50.5%) 1 (50.0%) 
1800 2 (6.3%) 10 and 14  0 0 1 (50.0%) 
Total 32 (100%) 1 to 14 6 (18.8%) 10 (31.2%) 3 (9.4%) 
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